Group 1 - Company GuoDeWei plans to repurchase shares with a total investment of between 100 million to 150 million yuan, with a maximum repurchase price of 53 yuan per share, expecting to buy back between 1.89 million to 2.83 million shares, accounting for 0.78% to 1.17% of total share capital [1] - Company Shuangliang Energy has won a bid for the Gansu Energy Chemical Qinyang 2×660MW coal power project, with a total bid amount of 237 million yuan, representing 1.82% of the company's projected revenue for 2024 [1] - Company China Pacific Insurance reported a total premium income of 227.17 billion yuan from its two subsidiaries in the first five months, with a year-on-year growth of 10.2% for its life insurance subsidiary and 0.5% for its property insurance subsidiary [1][2] Group 2 - Company LuKang Pharmaceutical has received a drug registration certificate for injectable Cefoperazone Sodium, a third-generation cephalosporin with broad-spectrum antibacterial properties [3] - Company 吉祥航空 reported a 4.97% year-on-year increase in passenger turnover in May, with a seat occupancy rate of 86.14%, up 3.70% year-on-year [4][5] - Company DuRui Pharmaceutical's subsidiary has also received a drug registration certificate for injectable Cefoperazone Sodium [6] Group 3 - Company KeLan Software announced that part of the shares held by its controlling shareholder will be auctioned, involving 5.09 million shares, accounting for 1.07% of the total share capital [7] - Company HuaCan Optoelectronics received a government subsidy of 87.84 million yuan, which is expected to positively impact the company's pre-tax profit for 2025 [8] - Company JinZhi Technology has won a bid for projects from the State Grid and China Resources New Energy, with a total bid amount of 84.41 million yuan [9] Group 4 - Company Vision China completed a capital increase for its subsidiary, raising 100 million yuan to accelerate its layout in the AI field [11] - Company Youa Co. received a profit distribution of 96.03 million yuan from its investment in Changsha Bank [13] - Company WanBangde's subsidiary obtained a patent for a deuterated compound, enhancing the chemical stability and reducing toxicity [16] Group 5 - Company DongCheng Pharmaceutical completed the enrollment of all 488 participants in the Phase III clinical trial for Fluorine-18 PSMA peptide injection, aimed at prostate cancer diagnosis [17] - Company China Merchants Expressway announced that its first phase of medium-term notes for 2024 will pay interest on July 2, 2025, with a total issuance of 2.5 billion yuan and an interest rate of 2.35% [18] - Company JinPu Titanium's subsidiary has temporarily suspended production for maintenance due to falling product prices and high production costs [20] Group 6 - Company BeiLu Pharmaceutical received a marketing authorization for Iodinated Contrast Injection in Hungary, marking another approval in the EU [22] - Company LiXing Co. obtained an overseas investment certificate for its wholly-owned subsidiary in Singapore, with a total investment of 2.16 million yuan [24] - Company LangKun Technology won a garbage collection service project with a bid amount of 21.57 million yuan [26] Group 7 - Company KeRui International plans to transfer 55% of its subsidiary Tianjin ZhiRui's equity for 41.96 million yuan [28] - Company Nanjing JuLong intends to invest 130 million yuan to build a production project for special materials with an annual output of 40,000 tons [30] - Company NanShan Intelligent plans to use up to 50 million yuan of idle funds for cash management in safe and liquid financial products [32] Group 8 - Company GuangLian Aviation completed the business change registration for its subsidiary, involving the introduction of strategic investors [34] - Company XiaoFang Pharmaceutical signed a cooperation agreement to develop a new drug for hair loss treatment [36] - Company GuiZhou SanLi plans to sign a 150 million yuan technology transfer and development contract with Guangdong Pharmaceutical University [38] Group 9 - Company ST SiLong's subsidiary received a drug registration certificate for Famotidine injection, used for treating upper gastrointestinal bleeding [52] - Company ZhongKe Information's executive plans to reduce holdings of up to 180,000 shares, accounting for 0.06% of total share capital [53] - Company KeLun Pharmaceutical's injectable Cefoperazone Sodium/Chloride Sodium injection received drug registration approval [54] Group 10 - Company LuXin Investment plans to transfer 10.06% of its stake in LuXin HuiJin for 203 million yuan, aiming to focus on its main business [56] - Company Western Gold plans to acquire 100% of Xinjiang MeiSheng for 1.655 billion yuan [58] - Company JinTou City Development intends to swap assets worth 5.862 billion yuan, changing its main business to urban centralized heating [60]

Group 1 - The company announced an adjustment to the conversion price of its convertible bonds, "恒逸转债," from 10.91 yuan/share to 9.20 yuan/share, effective from November 2024 [2][3] - The adjustment is based on the company's annual equity distribution, which includes a cash dividend of 0.50 yuan per 10 shares, resulting in a total cash dividend of approximately 165 million yuan [5][6] - The new conversion price after the adjustment will be 9.15 yuan/share, calculated by deducting the cash dividend from the previous conversion price [6] Group 2 - The company has a history of adjusting the conversion price of its bonds due to annual equity distributions, with previous adjustments made in 2021 and 2022 [1][2] - The conversion period for "恒逸转债" is set from April 22, 2021, to October 15, 2026 [6] - The company ensures that the total share capital remains unchanged after the equity distribution, maintaining the principle of unchanged market value [5]

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 一、回购股份基本情况 恒逸石化股份有限公司（以下简称"公司"或"恒逸石化"）于 2024 年 10 月 22 日召开的第十二届董事会第十五次会议审议通过了《关于以集中竞价交易方式回 购公司股份方案（第五期）的议案》。同意公司使用自有资金及股票回购专项贷 款资金，以集中竞价交易方式回购公司股份，回购资金总额不低于人民币 12,500 万元，不超过人民币 25,000 万元；回购价格为不超过人民币 9.00 元/股；回购期 限为公司自董事会审议通过本回购方案之日起 12 个月内。具体内容详见公司在 巨潮资讯网上披露的《关于以集中竞价交易方式回购股份方案（第五期）暨取得 金融机构股票回购专项贷款的公告》（公告编号：2024-110）、《关于以集中竞 价交易方式回购股份（第五期）的回购报告书》（以下简称"回购报告书"）（公 告编号：2024-111）。 二、2024年年度权益分派实施情况 证券代码：000703 证券简称：恒逸石化 公告编号：2025-061 恒逸石化股份有限公司 公司2024年年度权益分派方 ...

Core Viewpoint - The company has approved the 2024 annual equity distribution plan, which includes a cash dividend of 0.50 RMB per 10 shares, with a total cash distribution amounting to 165,017,526.75 RMB, after excluding repurchased shares from the total share count [1][3][4]. Group 1: Equity Distribution Plan - The equity distribution plan is based on a total share count of 3,666,321,624 shares, minus 365,971,089 repurchased shares, resulting in a base of 3,300,350,535 shares for the cash dividend calculation [3][4]. - The cash dividend per share is calculated as 0.0450090 RMB, which will be used to adjust the ex-dividend price accordingly [2][6]. - The ex-dividend date is set for June 20, 2025, with the record date being June 19, 2025 [5]. Group 2: Shareholder Rights and Taxation - Shares held in the company's repurchase account will not participate in the profit distribution, meaning those shares are excluded from the dividend calculation [3][4]. - Different tax rates apply for various categories of shareholders, with specific provisions for foreign investors and domestic funds regarding dividend tax [4][5]. Group 3: Convertible Bonds Adjustment - The conversion prices for the company's convertible bonds will be adjusted following the equity distribution, with "恒逸转债" changing from 9.20 RMB to 9.15 RMB per share, and "恒逸转2" from 10.41 RMB to 10.36 RMB per share, effective from June 20, 2025 [5][6].

证券代码：000703 证券简称：恒逸石化 公告编号：2025-061 恒逸石化股份有限公司 关于实施2024年年度权益分派后调整股份回购价格上限的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 一、回购股份基本情况 2025-053）。本次权益分派方案的具体内容为：以公司现有总股本3,666,321,624 股扣除公司回购专户上已回购股份数量365,971,089股后的股份数3,300,350,535 股为基数，每10股派发现金红利0.50元（含税），不送红股、不进行公积金转增 股本。 鉴于公司回购专用证券账户上的股份不参与2024年年度权益分派，公司本次 实际现金分红的总金额=实际参与分配的总股本*分配金额，即3,300,350,535股 *0.05元/股= 165,017,526.75元人民币。本次权益分派实施后，根据股票市值不变 原则，实施权益分派前后公司总股本保持不变，现金分红总额分摊到每一股的比 例将减小。因此，本次权益分派实施后除息价格计算时，每股现金红利应以 0.0450090元/股计算（每股现金红利=现金分红总额/总股本，即 ...

| 证券代码：000703 | 证券简称：恒逸石化 | 公告编号：2025-059 | | --- | --- | --- | | 债券代码：127022 | 债券简称：恒逸转债 | | 恒逸石化股份有限公司 关于"恒逸转债"转股价格调整的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 一、基本情况 恒逸石化股份有限公司（以下简称"公司"）于2020年10月16日公开发行了 2,000万张可转换公司债券（以下简称"恒逸转债"），转股价格11.50元/股，可 转债于2020年11月16日在深圳证券交易所上市交易，债券简称"恒逸转债"，债 券代码"127022"。 由于公司实施2020年年度权益分派，可转债转股价格由11.50元/股调整为 11.20元/股，相关事项详见2021年6月29日刊载于《证券时报》《中国证券报》《证 券日报》《上海证券报》和巨潮资讯网（www.cninfo.com.cn）上的《关于可转债 转股价格调整的公告》（公告编号：2021-075）。 由于公司实施2023年年度权益分派，可转债转股价格由11.00元/股调整为 10 ...

1 一、股东大会审议通过权益分派方案情况 | 证券代码：000703 | 证券简称：恒逸石化 | 公告编号：2025-058 | | --- | --- | --- | | 债券代码：127022 | 债券简称：恒逸转债 | | | 债券代码：127067 | 债券简称：恒逸转 2 | | 恒逸石化股份有限公司 2024年年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 恒逸石化股份有限公司（以下简称"恒逸石化"或"公司"）2024年年度权 益分派方案已获2025年5月15日召开的2024年年度股东大会审议通过，本次权益 分派方案的具体内容为：以公司现有总股本剔除已回购股份365,971,089股后的 3,300,350,535股为基数，向全体股东每10股派0.50元人民币现金，不送红股、不 进行公积金转增股本。在本分配预案实施前，公司总股本由于可转债转股、股份 回购、股权激励行权、再融资新增股份上市等原因而发生变化的，公司将维持每 股分配金额不变，相应调整总股本。 公司本次实际现金分红的总金额=实际参与分配的总股本×分配金额， ...

关于"恒逸转2"转股价格调整的公告 | 证券代码：000703 | 证券简称：恒逸石化 | 公告编号：2025-060 | | --- | --- | --- | | 债券代码：127067 | 债券简称：恒逸转 2 | | 恒逸石化股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 一、基本情况 恒逸石化股份有限公司（以下简称"公司"）于2022年7月21日公开发行了 3,000万张可转换公司债券（以下简称"恒逸转2"），初始转股价格10.50元/股， 恒逸转2于2022年8月18日起在深圳证券交易所挂牌交易，债券简称"恒逸转2"， 债券代码"127067"。 由于公司实施2023年年度权益分派，可转债转股价格由10.50元/股调整为 10.41元/股，相关事项详见2024年6月20日刊载于《证券时报》《中国证券报》《证 券日报》《上海证券报》和巨潮资讯网（www.cninfo.com.cn）上的《关于"恒逸 转2"转股价格调整的公告》（公告编号：2024-053）。 二、关于可转债转股价格调整的相关事项 （一）转股价格调整的相关依据 ...

Group 1 - The polyester market is experiencing price fluctuations and promotional activities, with factories implementing price cuts and production reductions to alleviate inventory pressure [1][3][5] - From January to May 2023, the polyester market faced high volatility due to weak demand and macroeconomic disturbances, leading to a generally weak market environment [2][3] - Major polyester companies are reducing production to manage inventory levels, with some firms having already implemented multiple rounds of production cuts [3][5] Group 2 - The polyester industry is seeing a shift towards high-value products as leading companies seek to enhance profitability and resilience against risks [3][4][6] - The market is expected to continue experiencing high volatility in the second half of 2023, influenced by macroeconomic pressures and changes in supply-demand dynamics [5][6] - The industry faces significant challenges, necessitating collaboration among government, industry associations, and enterprises to explore new development opportunities for sustainable growth [6]

Investment Rating - The report maintains an "Overweight" rating for the chemical industry, particularly focusing on nylon and specialty nylon supply chains [5]. Core Insights - Recent accidents in chemical enterprises have disrupted the supply of chemical products such as caprolactam, with a significant incident occurring at China Pingmei Shenma Group's nylon technology company, affecting its production capacity [1]. - The nylon market is highlighted for its excellent performance and broad downstream applications, with notable consumption increases in nylon 6 and nylon 66, which together account for approximately 90% of total nylon consumption [2]. - The report emphasizes the trend of domestic substitution in the specialty nylon market, with companies like Qicai Chemical and Sinochem International making significant advancements in production capabilities [2]. Summary by Sections Chemical Industry Overview - The report discusses the impact of recent safety incidents on the supply of caprolactam and other chemical products, indicating a potential 5.6% reduction in supply due to these disruptions [3]. - It suggests that leading companies in the chemical sector will benefit from stricter safety production controls and advanced production technologies [1]. Nylon and Specialty Nylon - Nylon is characterized as a thermoplastic resin with excellent mechanical strength and wear resistance, with significant applications in both civilian and industrial sectors [2]. - The report notes that nylon 6 and nylon 66 have seen consumption increases of 22.2% and 41.2% respectively in 2024, with recommended companies for investment including Polyone and Taihua New Materials [2]. Caprolactam and Related Companies - Caprolactam is identified as a crucial organic chemical raw material, with China's current production capacity at 7.1 million tons per year [3]. - The report recommends focusing on companies such as Luxi Chemical, Hualu Hengsheng, and Hengyi Petrochemical, which are involved in caprolactam production [3]. Investment Recommendations - The report suggests a continued focus on undervalued, high-dividend, and well-performing companies in the oil and gas sector, including China National Petroleum, Sinopec, and CNOOC [3]. - It also highlights the potential benefits for domestic material companies under the trend of domestic substitution, recommending companies like Jingrui Electric Materials and Tongcheng New Materials [3].